Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.4% After Insider Selling

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price was down 4.4% during trading on Tuesday after an insider sold shares in the company. The company traded as low as $12.10 and last traded at $12.10. Approximately 38,531 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 75,509 shares. The stock had previously closed at $12.66.

Specifically, President Songjiang Ma sold 2,000 shares of the business's stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the sale, the president now directly owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. The trade was a 0.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Gyre Therapeutics Stock Down 4.4 %

The business's 50 day moving average is $12.64 and its 200-day moving average is $12.67.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC bought a new stake in Gyre Therapeutics during the 3rd quarter valued at approximately $47,000. Barclays PLC lifted its holdings in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after buying an additional 6,855 shares during the last quarter. Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the second quarter worth $218,000. 23.99% of the stock is owned by institutional investors and hedge funds.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.